Browse our anti-LCAT (LCAT) Antibodies

Human Lecithin-Cholesterol Acyltransferase (LCAT) interaction partners

1. Single Nucleotide Polymorphism in LCAT gene is associated with dyslipidemia.

2. data suggests a model wherein the active site of LCAT is shielded from soluble substrates by a dynamic lid until it interacts with HDL (show HSD11B1 Antibodies) to allow transesterification to proceed

3. Increased LCAT activity may be associated with increased formation of triglyceride rich lipoproteins, leading to a reduction in LDL particle size and atherosclerosis.

4. Mapping the naturally occurring mutations onto the structure provides insight into how they may affect LCAT enzymatic activity.

5. Report slightly reduction in LCAT that would probably reflect a delay in reverse cholesterol transport occurring in MetS (show ETV3 Antibodies).

6. rs5923 polymorphism is not associated with low high-density lipoprotein cholesterol(HDL (show HSD11B1 Antibodies)-C)levels in Iranian population

7. increased cholesterol esterification by LCAT is atheroprotective

8. The data indicate that this novel apoA-I (show APOA1 Antibodies) missense is associated with markedly decreased levels of HDL (show HSD11B1 Antibodies) cholesterol and very large alpha-1 HDL (show HSD11B1 Antibodies), as well as decreased serum cellular cholesterol efflux and LCAT activity

9. A robust all-atom model for LCAT generated by homology modeling

10. This study investigated how the natural LCAT[T147I] and LCAT[P274S] mutations affect the pathway of biogenesis of high-density lipoproteins.

Mouse (Murine) Lecithin-Cholesterol Acyltransferase (LCAT) interaction partners

1. Taken together, these results suggest that apoE (show APOE Antibodies)-containing discoidal HDLs (show CSF1R Antibodies) do not require LCAT-dependent maturation to mediate efficient Abeta (show APP Antibodies) clearance

2. increased cholesterol esterification by LCAT is atheroprotective

3. Gene transfer of WT LCAT in LCAT(-/-) mice increased 11.8-fold the plasma cholesterol, whereas the LCAT[T147I] and LCAT[P274S] mutants caused a 5.2- and 2.9-fold increase, respectively.

4. DYRK1A (show DYRK1A Antibodies) overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I (show APOA1 Antibodies) levels.

5. adrenal glucocorticoid function in LCAT knockout (KO) mice

6. a novel function of apoA-IV (show APOA4 Antibodies) in the biogenesis of discrete HDL (show HSD11B1 Antibodies)-A-IV particles with the participation of ABCA1 (show ABCA1 Antibodies) and LCAT

7. Studies suggest that absence of lecithin cholesterol acyltransferase (LCAT) may protect against insulin (show INS Antibodies) resistance, diabetes and obesity.

8. Data show that LCAT activity was significantly higher in long chain base biosynthesis protein 2 (Sptlc2 (show SPTLC2 Antibodies))+/- and sphingomyelin synthase 2 (Sms2 (show SGMS2 Antibodies))-/- mice, but markedly lower in ApoE (show APOE Antibodies)-/- and Ldlr (show LDLR Antibodies)-/- mice.

9. LCAT deficiency confers gender-specific protection against diet-induced obesity and insulin (show INS Antibodies) resistance at least in part through regulation in UPR, white adipose tissue adipogenesis, and brown adipocyte partitioning

10. Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E (show APOE Antibodies) knockout background in association with a reduction in atherosclerosis

Rabbit Lecithin-Cholesterol Acyltransferase (LCAT) interaction partners

1. LCAT cholesterol esterification is associated with the increase of ApoE (show APOE Antibodies)/ApoA-I (show APOA1 Antibodies) ratio during atherosclerosis progression in rabbit.

Pig (Porcine) Lecithin-Cholesterol Acyltransferase (LCAT) interaction partners

1. The 1,434 bp mRNA sequence of porcine LCAT including the full coding region and encoding a protein of 472 amino acids, was obtained.